Eli Lilly and Company v. Canada

Eli Lilly and Company v. Canada. Eli Lilly and Company, a United States pharmaceutical corporation, brought an investor–state arbitration claim under the North American Free Trade Agreement against Canada challenging decisions of the Canadian Intellectual Property Office regarding patents for pharmaceuticals. The dispute engaged complex issues in intellectual property, administrative law, international arbitration, and public health policy and produced awards that affected debate among World Trade Organization, United States Chamber of Commerce, Organisation for Economic Co-operation and Development, European Union, and World Health Organization stakeholders.

Background

Eli Lilly and Company, founded by Eli Lilly and headquartered in Indianapolis, is known for pharmaceutical products such as Prozac, Cialis, and Zyprexa; the company initiated arbitration after Canada, through the Canadian Intellectual Property Office and judicial review in the Supreme Court of Canada, invalidated patents for drugs including Strattera and Axiron. The claimant relied on investor protections under Chapter 11 of the North American Free Trade Agreement, an agreement involving United States, Canada, and Mexico, invoking standards such as fair and equitable treatment, national treatment, and indirect expropriation as applied to intellectual property rights adjudicated by tribunals like the International Centre for Settlement of Investment Disputes and the Permanent Court of Arbitration. The contested patents had been subject to proceedings before the Federal Court of Canada and appeals to the Federal Court of Appeal and the Supreme Court of Canada, where doctrines such as obviousness, utility, and promise doctrine featured prominently.

Proceedings and Legal Issues

The arbitration, administered under rules used by institutions such as the International Chamber of Commerce, required the tribunal to consider jurisdictional questions and merits implicating doctrines from the Patent Act (Canada) and standards from investor–state jurisprudence developed in cases like CMS Gas Transmission Company v. Argentina and Metalclad Corporation v. Mexico. Key legal issues included whether decisions of national administrative tribunals constituted expropriation under international law, whether substantive patent law recourse could be characterized as denial of fair and equitable treatment, and whether the tribunal had jurisdiction over measures alleged to be regulatory actions by entities such as the Canadian Intellectual Property Office and courts including the Supreme Court of Canada. The parties submitted evidence and expert reports on pharmaceutical regulation, clinical trials, and patent examination practices involving institutions like Food and Drug Administration, European Medicines Agency, and academic centers such as Harvard Medical School and University of Toronto.

Decision and Reasoning

In a partial award on jurisdiction and admissibility issued in 2017 and a final award concluded in 2019, the tribunal, chaired by arbitrator Thomas Wälde, dismissed many of Eli Lilly's claims and denied monetary relief, applying interpretive approaches influenced by precedents from International Law Commission writings, arbitral awards such as Pope & Talbot Inc. v. Canada, and principles articulated in instruments like the United Nations Convention on Contracts for the International Sale of Goods. The tribunal analyzed standards such as denial of justice under customary international law and the scope of indirect expropriation, referencing case law including ADC Affiliate Limited v. Hungary and Metalpar S.A. v. Chile. It found that the contested judicial and administrative decisions fell within Canada’s regulatory prerogatives and did not amount to international unlawful expropriation or breach fair and equitable treatment; the tribunal assessed patentability doctrines including obviousness and utility against evidence from patent offices like the European Patent Office and scholarly commentary from institutions such as Stanford Law School and Yale Law School.

Impact and Reactions

The award prompted responses across policy networks including the United Nations Conference on Trade and Development, Canadian Bar Association, Pharmaceutical Research and Manufacturers of America, and civil society groups such as Médecins Sans Frontières. Proponents of investor–state dispute settlement, including delegations from the United States Department of Commerce and business federations like the National Association of Manufacturers, emphasized investment protection; critics, represented by advocacy organizations and academic centers at McGill University and London School of Economics, argued the case illustrated tensions between investor rights and domestic public health regulation. Legislatures and treaty negotiators in contexts like the Comprehensive and Progressive Agreement for Trans-Pacific Partnership and discussions at the World Intellectual Property Organization cited the award in debates on reforming protections for intellectual property and revising investor–state mechanisms.

Subsequent Developments and Legacy

Post-award, the decision influenced litigation strategy for multinational firms such as GlaxoSmithKline and Novartis and informed policy reforms in Canada and treaty practice involving United Kingdom, Australia, and New Zealand. The case contributed to scholarship at universities including Columbia Law School and University of Cambridge on the intersection of patent law and international investment law and spurred legislative reviews of treaty provisions in parliaments like the Parliament of Canada and the United States Senate. Its legacy continues to shape arbitration practice at institutions such as the Permanent Court of Arbitration and discussion in forums like the World Economic Forum and G20 Summit on balancing investor protections with regulatory autonomy. Category:International arbitration cases